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Abstract
Introduction: Leptin has a prominent role in the development and maintenance of acute and chronic
inflammatory states such as rheumatoid arthritis (RA) and obesity. Nevertheless, the association of serum leptin
(sLep) and soluble leptin receptor (sLepR) in RA pathogenesis has not been clarified. The purpose of this study was
to evaluate the association of sLep, sLepR and leptin production indexes such as sLep/fat mass ratio with clinical
activity and biomarkers and anti-cyclic citrullinated peptide (anti-CCP) antibodies in RA compared with body mass
index (BMI) matched control subjects.
Methods: We included 64 RA patients and 66 controls matched for age, gender and BMI. Subjects were evaluated
for BMI, fat mass distribution, sLep, sLepR, sLep/fat mass ratio and sLepR/fat mass ratio. Patients were evaluated for
clinical activity and anti-CCP antibodies.
Results: We found two or three fold increased sLep levels, sLep/sLepR ratio and sLep/fat mass ratio in obese anti-
CCP positive RA patients vs. controls. Partial correlations showed that anti-CCP antibodies were correlated with
sLep/fat mass ratio (partial r = 0.347, P = 0.033) after adjustment for age, subcutaneous adipose tissue and fat mass.
Conclusions: In preobese and obese RA patients there is and increased production of sLep according to anti-CCP
positivity. This phenomenon suggests there is an additive effect of chronic inflammation resulting from RA and
obesity in which leptin favors the humoral response against citrullinated proteins. In summary, the data observed in
our study suggests sLep could be a surrogate marker of chronicity and humoral immunity in RA in the presence of
obesity.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease characterized by joint destruction
and disability [1]. The role of proinflammatory cytokines
is well-defined in the mechanism of disease in local
damage such as pannus formation and bone erosion [1].
In addition, proinflammatory cytokines might contribute
to the development of metabolic dysfunction in RA [2].
Adipokines have gained a prominent role within the last
decade in the understanding of pathogenesis of chronic
diseases (RA, obesity, metabolic syndrome and type 2
diabetes mellitus) [1, 3], through the maintenance of
chronic inflammation within the joints or systemically
[4]. From the adipokines described so far, the role of lep-
tin is prominent.
Leptin is a non-glycosylated 16 kDa protein from the
type I cytokine superfamily that is mainly produced by
adipose tissue [5, 6]. Besides the biological function of
leptin in food intake and energy expenditure, its role in
immune regulation has been acknowledged due to its ef-
fects in both innate and adaptive immunity [4, 7]. Leptin
signaling is transduced by leptin receptor (LepR), a
transmembrane protein of 170 kDa that belongs to the
family of type 1 cytokine receptors. Five isoforms of
LepR in humans have been described; the isoforms “a”
through “d”, are transmembrane proteins obtained by al-
ternative splicing, while, isoform “e” corresponds to sol-
uble leptin receptor (sLepR) obtained by proteolytic
shedding of transmembrane isoforms [8].
sLepR could regulate leptin action through high affin-
ity binding of free leptin, preventing its degradation and
clearance, but also by avoiding leptin binding to trans-
membrane receptors and activation of signaling through
the signal transducer and activator of transcription 3
protein (STAT3) [9–11]. Increased expression of sLepR
is associated with lower body weight in murine models,
suggesting the important role of sLepR in leptin regula-
tion [12]. Reduction of sLepR levels occur in progression
of obesity with fat mass accumulation, turns into more
bioactive leptin for signaling through transmembrane re-
ceptors [13–15]. Chronically high levels of leptin may
provoke reduced LepR signaling due to a mechanism
that is not yet completely elucidated, leading to leptin
resistance [16, 17].
Despite the extensive study of leptin in RA there is still
no consensus on the role of this molecule in RA patho-
genesis. Previous studies included small numbers of pa-
tients without a clear cutoff for body mass index (BMI),
resulting in non-reproducible associations. In general,
serum levels of leptin are more elevated in RA patients
than controls and are correlated with body fat mass and
BMI [18–20]. Leptin levels are lower in synovial fluid
than in plasma and correlate with intra-articular white
blood cell count suggesting in situ consumption [21].
Moreover, in vitro leptin may induce production of
interleukin (IL)-6 in fibroblast-like synoviocytes and IL-8
via janus kinase (JAK)2-STAT3 signaling [22, 23]. In
vivo, leptin has been correlated with erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), change
in disease activity score in 28 joints (DAS28), erosive
disease and progression in the Sharp/van der Heijde
score [24–27].
In this study, we evaluated RA patients without trad-
itional cardiovascular risk factors classified by anti-cyclic
citrullinated peptide (anti-CCP) positivity, measuring
serum leptin (sLep), sLepR, sLep/sLepR ratio and other
metabolic parameters, namely proinflammatory cyto-
kines, BMI and adiposity.
Methods
Study groups
We included patients with RA attending the rheumatol-
ogy service of Hospital Civil “Dr. Juan I. Menchaca”,
Guadalajara, Jalisco, Mexico. To be eligible for the study,
patients had to be 18 years of age or older and meet the
American College of Rheumatology criteria (ACR 1987)
[28]. For the control group we included volunteers from
the open population, who were matched by age, gender
and BMI with the RA subjects. We excluded subjects
with: previous history of smoking or who were current
smokers; cardiovascular disease (CVD); hypertension;
diabetes mellitus type 2; thyroid disease; renal impair-
ment; malignancy; hepatic disease or hyperlipidemia. We
also excluded patients previously treated with high doses
of steroids (>10 mg/day prednisone or equivalent, in-
cluding those given by intravenous administration).
Ethics
This protocol was approved by the Institutional Re-
view Board (IRB) committee of “Hospital Civil Juan I.
Menchaca”, registered under the number 1068/10.
Written consent was obtained from all subjects who
participated in the study. Research was conducted ac-
cording to Declaration of Helsinki.
Subject assessment
Height was measured using a stadiometer (Seca GmbH
& Co. KG. Hamburg, Germany) to the nearest 1.0 mm.
Body weight (to the nearest 0.01 kg), BMI and fat mass
were determined by bio-electrical impedance analysis
(Tanita BC418® Tokyo, Japan). All subjects were classi-
fied by BMI according to World Health Organization
(WHO) criteria as: normal weight (BMI 18.50–
24.99 kg/m2), preobese (BMI 25.00–29.99 kg/m2) or
obese (BMI ≥30.00 kg/m2) [29]. Sagittal abdominal
diameter (SAD) and waist and hip circumference were
measured to the nearest 0.1 cm using an anthropo-
metric fiberglass tape, Gulick® length 0–180 cm
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precision ±1 mm (North Coast Medical Inc., Gilroy,
CA, USA) in accordance with the procedures recom-
mended by Durnnin [30]. Four measures (in millime-
ters) of skinfold thickness (biceps, triceps, subscapular
and supra-iliac) were obtained on the left side of the
body using a Harpenden skinfold caliper (opened
80 mm and precision of ± 0.2 mm, constant pressure
10 g/mm2; Holtain Ltd. Crosswell, Crymych, UK.) and fol-
lowing the procedures recommended by the anthropo-
metric indicators measurement guide.
We calculated the waist to hip ratio (WHR), body fat
ratio:
BFR ¼ Body fat mass kgð Þ=Height m2  ;
as an indicator of adiposity, visceral fat area:
ðVFA ¼ 6:47  SAD þ 186:81  WHR – 10:77
 Sex man ¼ 1; woman ¼ 2ð Þ þ 0:94  Age
þ 0:83  Body mass kgð Þ – 290:31Þ
[31],
as an indicator of preferential accumulation of fat in
the abdomen rather than on the limbs, and the sum of
the four skinfold thicknesses (S4ST) as an indicator of
subcutaneous fat. Disease activity was measured in RA
patients using the DAS28-based CRP and ESR [32].
Laboratory techniques and procedures
We obtained venous blood samples that were allowed to
clot at room temperature and were subsequently centri-
fuged at 1,500 relative centrifugal force (RCF) (Rotanta
460R, Andreas Hettich GmbH & Co. KG. Germany) for
ten minutes. The serum was stored at −70 °C until
analysis.
ESR was measured using the Wintrobe method [33].
CRP, rheumatoid factor (RF) and glucose levels were
measured by standard techniques (RANDOX Laborator-
ies Limited, Crumlin, UK). Serum insulin (limit of detec-
tion 0.399 μΙU/mL, ALPCO Diagnostics, Salem, NH,
USA), sLep and sLepR limit of detection 0.4 ng/mL and
tumor necrosis factor α (TNFα), limit of detection of
8.43 pg/mL (Enzo Life Sciencies, Inc. New York, NY,
USA) and, anti-CCP antibodies, U/mL (Axis-Shield Diag-
nostics Ltd., Dundee, Scotland), were measured by the
ELISA method. We put forward the follow new indexes as
indicators of leptin production: 1) sLep (ng/mL)/sLepR
(ng/mL), 2) sLep (ng/mL)/fat mass (kg) and 3) sLepR (ng/
mL)/fat mass (kg).
Table 1 Demographic and clinical characteristics of the groups studied
Normal weight Preobese Obese
Measurement Control RA P Control RA P Control RA P
n = 21 n = 21 n = 26 n = 21 n = 19 n = 22
Age, years 34 ± 11 39 ± 12 0.127 43 ± 12 47 ± 10 0.230 46 ± 9 41 ± 9 0.076
Body weight, kg 60 ± 7 57 ± 6 0.126 68 ± 6 69 ± 5 0.578 91 ± 18 82 ± 9 0.060
BMI, kg/m2 22.00 ± 1.78 22.13 ± 2.27 0.845 27.26 ± 1.16 27.50 ± 1.28 0.498 35.03 ± 6.79 33.55 ± 2.75 0.384
Body fat mass, % 26.36 ± 5.66 25.95 ± 6.79 0.834 36.20 ± 3.24 36.21 ± 3.21 0.991 38.78 ± 8.19 42.35 ± 5.00 0.095
Body fat mass, kg 15.86 ± 3.87 14.67 ± 4.29 0.353 24.54 ± 4.84 24.88 ± 3.24 0.784 35.58 ± 12.01 34.81 ± 7.17 0.806
Body fat ratio, kg/m2 5.83 ± 1.47 5.80 ± 1.83 0.958 9.94 ± 1.54 9.97 ± 1.15 0.942 13.86 ± 5.25 14.29 ± 2.60 0.739
VFA, cm2 46.38 ± 26.58 77.12 ± 43.28 0.021 81.26 ± 23.62 119.52 ± 35.22 <0.001 106.43 ± 30.24 131.83 ± 21.97 0.036
S4ST, mm 52.08 ± 13.67 49.17 ± 14.48 0.513 105.94 ± 20.79 70.56 ± 19.21 <0.001 90.06 ± 16.94 76.34 ± 23.01 0.015
ESR, mm/h 9.76 ± 6.32 19.38 ± 9.82 0.001 21.19 ± 10.08 17.10 ± 12.14 0.213 14.21 ± 10.20 27.33 ± 14.08 <0.001
CRP, mg/L 5.22 ± 2.72 7.66 ± 7.08 0.153 3.56 ± 3.07 8.83 ± 6.67 0.005 8.66 ± 4.70 11.02 ± 9.19 0.112
Glucose mg/dL 94.43 ± 14.03 96.90 ± 14.27 0.574 93.42 ± 27.18 100.80 ± 16.33 0.223 101.37 ± 11.36 98.25 ± 10.81 0.386
Insulin, μΙU/mL 6.97 ± 6.97 14.43 ± 10.82 0.005 9.98 ± 6.56 14.76 ± 16.54 0.268 12.81 ± 8.35 23.16 ± 44.60 0.240
HOMA-IR 1.49 ± 1.16 3.61 ± 2.98 0.003 2.34 ± 1.59 4.34 ± 4.98 0.171 3.28 ± 2.25 5.58 ± 10.92 0.278
Leptin, ng/mL 30.14 ± 20.69 45.98 ± 40.26 0.119 35.48 ± 12.32 121.65 ± 106.35 0.001 79.11 ± 45.20 188.21 ± 100.88 <0.001
sLepR, ng/mL 68.81 ± 24.02 60.02 ± 18.81 0.209 43.98 ± 15.24 51.34 ± 12.51 0.131 44.75 ± 14.91 37.49 ± 9.67 0.096
Leptin/sLepR 0.53 ± .50 0.98 ± 1.40 0.176 0.89 ± 0.41 2.45 ± 2.45 0.033 2.18 ± 1.62 5.67 ± 3.56 0.002
Leptin/FM, ng/mL/kg 1.87 ± 1.21 3.04 ± 1.95 0.027 1.41 ± 0.423 4.99 ± 4.48 0.002 2.18 ± 1.19 5.32 ± 2.67 <0.001
sLepR/FM, ng/mL/kg 4.59 ± 1.89 4.56 ± 2.33 0.964 1.83 ± 0.71 2.12 ± 0.53 0.196 1.49 ± 0.95 1.10 ± 0.41 0.113
Continuous variables are represented by mean ± standard deviation; means were compared with Student’s t test. RA rheumatoid arthritis, BMI body mass index,
VFA visceral fat area, S4AP sum of four skinfold thicknesses (bicipital, tricipital, subscapular and supra-iliac), ESR erythrocyte sedimentation rate, CRP C-reactive
protein, sLepR soluble leptin receptor), FM fat mass, HOMA-IR homeostatic model assessment-insulin resistance
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Homeostasis model assessment-insulin resistance
(HOMA-IR) was calculated [34] and individuals were
classified by Stern criteria as: individuals with insulin re-
sistance (IR) when BMI ≥27.5 kg/m2 and HOMA-IR
≥3.6 or HOMA-IR >4.65 independent of BMI, and indi-
viduals without IR when negative for one of the two
conditions [35].
Statistical analysis
Data were analyzed with the software SPSS v22.0 (SPSS
Inc., Chicago, IL, USA). Results are represented as mean
± SD or frequencies, accordingly. Continuous variables
were analyzed with Student’s t test or the Mann-
Whitney U test, accordingly. Qualitative variables were
analyzed with the chi square (χ2) or Fisher’s exact test.
The Pearson r correlation coefficient was calculated.
One-way analysis of variance (ANOVA) with Dunnet’s
T3 post hoc test was used to compare quantitative data
between groups. Statistical significance was considered
when P <0.05.
Results
Demographic and clinical characteristics
We evaluated 64 RA patients compared with 66 controls
matched by age and gender, classified according to BMI.
Age, gender, laboratory tests and metabolic parameters
are described in Table 1.
Table 2 Demographic and clinical characteristics of RA patients according to BMI
Measurement All Normal weight Preobese Obese
BMI 18.50–24.99 kg/m2 BMI 25.00–29.99 kg/m2 BMI ≥30.00 kg/m2
n = 64 n = 21 n = 21 n = 22
Female gender, n (%) 60 (93.8) 19 (90.5) 20 (95.2) 21 (95.5)
Time of disease evolution, years 5.34 ± 6.97 5.73 ± 8.95 5.06 ± 4.80 5.23 ± 6.78
Positive anti-CCP, n (%) 46 (71.9) 15 (71.4) 13 (61.9) 18 (81.8)
Anti-CCP, U/Ml 167.20 ± 305.49 179.03 ± 405.53 218.45 ± 338.76 107.00 ± 86.53
Positive RF, n (%) 41 (65.1) 13 (61.9) 15 (71.4) 13 (61.9)
RF, UI/Ml 79.39 ± 51.57 93.03 ± 43.26 79.65 ± 60.09 68.01 ± 47.61
ESR, mm/h 21.27 ± 12.74 19.38 ± 9.82 17.10 ± 12.14 27.33 ± 14.08b
CRP, mg/L 9.14 ± 7.71 7.66 ± 7.08 8.83 ± 6.67 11.02 ± 9.19
DAS-28-based CRP 3.40 ± 1.30 2.90 ± 1.20 3.82 ± 1.24 3.53 ± 1.36
TNFα, pg/Ml 57.05 ± 39.87 62.03 ± 34.40 60.93 ± 53.82 48.83 ± 27.48
sLep, ng/Ml 119.70 ± 104.64 45.98 ± 40.26a 121.65 ± 106.35 188.21 ± 100.88
sLepR, ng/Ml 50.45 ± 17.25 60.02 ± 18.81c 51.34 ± 12.51 37.49 ± 9.67
sLep/sLepR, ng/mL 2.87 ± 3.19 0.98 ± 1.40a 2.45 ± 2.45 5.67 ± 3.56
Insulin resistance, n (%) 18 (36.7) 5 (26.3) 5 (35.7) 8 (50.0)
Continuous variables are represented as mean ± standard deviation; qualitative variables are represented as number (%). Groups were compared with one-way
analysis of variance and Dunnet’s T3 post hoc test. aNormal weight vs. preobese and obese; bpreobese vs. obese; cNormal weight vs. obese. BMI body mass index,
anti-CCP anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, ESR erythrocyte sedimention rate, CRP C-Reactive protein, TNF tumor necrosis factor, sLep
soluble leptin), sLepR soluble leptin receptor, HOMA-IR homeostatic model assessment, DAS-28 disease activity index in 28 joints
Table 3 sLep, sLepR and respective fat mass ratios of RA patients according to BMI and anti-CCP status
Normal weight Preobese Obese
BMI 18.50–24.99 kg/m2 BMI 25.00–29.99 kg/m2 BMI ≥30.00 kg/m2
Anti-CCP
Measurement Negative Positive P Negative Positive P Negative Positive P
n = 6 n = 15 n = 8 n = 13 n = 4 n = 18
sLep, ng/Ml 51.09 ± 29.76 43.93 ± 44.54 0.267 66.90 ± 51.78 155.34 ± 118.56 0.104 104.04 ± 29.21 206.91 ± 101.91 0.033
sLepR, ng/Ml 60.46 ± 14.20 59.82 ± 21.13 0.898 56.47 ± 13.79 48.49 ± 11.55 0.518 45.89 ± 4.63 35.39 ± 9.55 0.101
sLep/sLepR, ng/Ml 0.89 ± .49 1.02 ± 1.69 0.244 1.36 ± 1.43 3.05 ± 2.75 0.240 2.13 ± 0.86 6.55 ± 3.43 0.048
sLep/fat mass, ng/mL/kg 3.44 ± 1.72 2.86 ± 2.08 0.564 2.73 ± 2.30 6.39 ± 4.98 0.053 3.27 ± 0.87 5.77 ± 2.73 0.033
sLepR/fat mass, ng/mL/kg 4.11 ± 1.01 4.78 ± 2.79 0.925 2.25 ± 0.65 1.99 ± 0.43 0.529 1.45 ± 0.27 1.01 ± 0.39 0.101
Continuous variables are represented as mean ± standard deviation; the Mann-Whitney U test was used to compare differences between groups. BMI body bas
index, anti-CCP anti-cyclic citrullinated peptide antibodies, sLep serum leptin, sLepR soluble leptin receptor)
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In patients with RA, fat mass distribution was different
to that in controls; RA patients had an increased VFA
and lower subcutaneous adipose tissue accumulation
(S4ST) than controls despite having similar BMI. In
addition, we observed a trend for increased basal insulin
and HOMA-IR in patients with RA vs. controls (Table 1).
RA patients had higher levels of sLep (115.91 ±
103.81 ng/mL vs. 46.33 ± 34.66 ng/mL, P <0.001) and
higher sLep/fat mass ratio (4.42 ± 1.02 ng/mL/kg vs.
1.79 ± 1.02 ng/mL/kg, P <0.001) than controls. There
was no difference in serum sLepR between RA pa-
tients and controls (2.75 ± 2.08 ng/mL vs. 2.63 ±
1.86 ng/mL, P = 0.755), data not shown.
We observed an increase in sLep levels and sLep/sLepR
ratio in obese and preobese RA patients in comparison
with controls. In addition, sLep levels and sLep/sLepR ra-
tio in RA patients were increased by fourfold to fivefold in
obese patients in comparison with normal-weight patients.
Patients with RA had more sLep per fat mass than con-
trols, according to the WHO classification (Table 1).
Fig. 1 Serum leptin (sLep), sLep/sLep receptor (sLepR) and leptin/fat mass ratio in controls and patients with rheumatoid arthritis (RA) according
to anti-cyclic citrullinated peptide antibodies (anti-CCP). Mean ± standard deviation of sLep (a), sLepR (b), leptin/sLepR (c), leptin/fat mass ratio (d)
and sLepR/fat mass ratio (e)
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The prevalence of IR, sLep and sLepR levels and sLep/
sLepR ratio in RA patients were as follows: obese > pre-
obese > normal weight, while for ESR levels they were
obese > preobese RA patients (Table 2).
In serum sLep from obese RA patients, the sLep/sLepR
ratio and sLep/fat mass ratio were higher according to posi-
tivity for anti-CCP antibodies (Table 3). In contrast, levels
of sLepR were lower with greater BMI (Fig. 1 and Table 3).
sLep, sLepR and sLep/sLepR were strongly correlated
with fat mass, BMI, insulin and HOMA-IR, as is shown
in Table 4. Levels of sLep were positively correlated with
ESR (Table 4). There was no correlation between sLep
or sLepR and other parameters including anti-CCP anti-
bodies. Notwithstanding, analysis of partial correlation
showed that anti-CCP antibodies were correlated with
sLep/fat mass ratio (partial r = 0.347, P = 0.033) after ad-
justment for age, S4ST and fat mass.
sLep and sLepR quartiles
When we classified sLep level by quartiles, we observed
increasing ESR, body fat ratio, HOMA-IR and decreas-
ing sLepR level. When we grouped the sLepR level by
quartiles, we observed increasing ESR, body fat ratio,
DAS28 ESR and DAS28 CRP (Table 5).
Discussion
In this study, we observed greater sLep levels and sLep/
sLepR ratio in RA patients compared to age-, gender-
and BMI-matched controls (Table 1); these associations
were more evident in RA patients who were overweight
or obese (Table 2). After normalization of sLep with fat
Table 4 Correlation between anti-CCP, leptin, sLepR, or leptin/
sLep, and adiposity, inflammatory and metabolic markers
Anti-CCP sLep sLepR sLep/sLepR
Measurement R r r r
P P P P
BMI, kg/m2 −0.154 0.494 −0.472 0.556
0.221 <0.001 <0.001 <0.001
Body fat mass, % −0.174 0.570 −0.458 0.587
0.166 <0.001 <0.001 <0.001
ESR, mm/h 0.137 0.257 −0.259 0.355
0.294 0.033 0.059 <0.001
CRP, mg/L 0.293 0.063 −0.177 0.092
0.021 0.597 0.205 0.515
sLep, ng/Ml −0.004 - −0.557 0.940
0.977 <0.001 <0.001
sLepR, ng/Ml −0.134 0.613 - −0.740
0.354 <0.001 <0.001
Insulin μUI/Ml −0.083 0.427 −0.148 0.314
0.567 0.001 0.286 <0.001
HOMA-IR −0.091 0.416 −0.072 0.236
0.533 0.002 0.607 0.092
Pearson r coefficient was calculated. Anti-CCP anti cyclic citrullinated peptide
antibodies, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, DAS-28 disease activity index in 28 joints, sLepR soluble leptin
receptor, FM fat mass, HOMA-IR, homeostatic model assessment-insulin resist-
ance. RF rheumatoid factor
Table 5 Adiposity, metabolic and inflammation markers in RA patients grouped by sLep and sLepR quartiles
sLep ng/Ml Quartile 1 Quartile 2 Quartile 3 Quartile 4
<36.27 36.27–72.75 72.76 –177.48 >177.48
n = 14 n = 16 n = 17 n = 17
Body fat ratio, kg/m2 5.92 ± 2.42 8.34 ± 2.90 11.16 ± 2.58 13.82 ± 3.43
ESR, mm/h 18.37 ± 10.53 19.37 ± 11.76 20.17 ± 13.14 27.17 ± 13.65
HOMA-IR 2.23 ± 2.11 3.52 ± 3.98 3.4 ± 2.55 8.25 ± 13.32
sLepR, ng/Ml 69.30 ± 17.62 48.24 ± 7.50 47.21 ± 11.48 36.48 ± 12.49
sLepR ng/Ml Quartile 4 Quartile 3 Quartile 2 Quartile 1
>59.35 48.74–59.34 38.83–48.73 <38.83
n = 11 n = 14 n = 11 n = 15
Body fat ratio, kg/m2 6.59 ± 2.63 8.77 ± 2.56 9.30 ± 4.49 11.59 ± 4.73
ESR, mm/h 15.91 ± 9.26 18.14 ± 10.52 19.50 ± 9.90 27.94 ± 12.64
DAS-28 (ESR) 3.08 ± 1.46 3.09 ± 1.25 3.74 ± 1.05 4.02 ± 1.45
DAS-28 (CRP) 2.86 ± 1.37 2.82 ± 1.19 3.39 ± 1.06 3.64 ± 1.43
FMI fat mass index, ESR erythrocyte sedimentation rate, HOMA-IR homeostatic model assessment insulin resistance, sLepR soluble leptin receptor, DAS-28 disease
activity score in 28 joints, CRP C-reactive protein
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mass (sLep/fat mass ratio), patients with RA also had
greater values of sLep (nanograms per milliliter) per
kilogram of fat mass in every BMI category (Table 1).
Considering this, patients with RA have greater leptin
resistance than that observed in obese controls [36, 37].
sLep, sLep/sLepR ratio and sLep/fat mass ratio in serum
from obese RA patients was higher according to positiv-
ity for anti-CCP antibodies. Agrawal et al., found that
leptin induced the release of IL-6, TNF-α and IL-10 by B
lymphocytes, high levels of leptin with high levels of
these proinflammatory cytokines, and a chronic inflam-
matory environment [38]. In RA proinflammatory cyto-
kines like TNF-α and IL-6 might also increase leptin
production by adipocytes, leading to chronic hyperlepti-
nemia and leptin resistance [39].
This is the first report showing increased leptin produc-
tion in association with anti-CCP status in preobese and
obese RA patients (Fig. 1a, 1d). This suggests that leptin
may be an important mediator for sustaining autoimmune
humoral responses in RA, especially in anti-CCP positive
patients. Leptin has a myriad of effects triggering or per-
petuating acute and chronic inflammation, locally or sys-
temically [40]. Leptin has a role in innate and adaptive
immunity, acting as an anti-inflammatory and proinflam-
matory mediator. Several studies have been performed to
investigate the signaling pathways at the molecular level,
to address the pleiotropic activity of leptin. Leptin is able
to trigger the phosphorylation of different pathways in-
volving extracellular-signal-regulated kinases (ERK)-1,
ERK-2, p38 mitogen-activated protein kinase (MAPK),
and phosphoinositide 3-kinase (PI3K) in peripheral
blood mononuclear cells (PBMCs) eliciting T cell pro-
liferation. Dendritic cell differentiation is favored by
STAT3 phosphorylation induced by leptin [41, 42]. In
adaptive immunity, leptin incentivizes T cell differen-
tiation towards T helper (Th)1 and Th17 effector
cells, activation of B cells, and inhibition of T regula-
tory (Treg) cell proliferation [43].
Leptin blockade in experimental autoimmune enceph-
alomyelitis (EAE) improves clinical score, disease pro-
gression and relapses by inhibition of T cell proliferation
and cytokine secretion toward a Th2/regulatory profile
[44]. In a report of Amarlyo et al. [45] leptin levels were
increased in lupus patients, and in murine models leptin
promotes the survival and proliferation of autoreactive T
cells, explained by upregulation of B cell lymphoma 2
protein (Bcl-2).
Some previous reports on leptin in RA did not report
correlation with clinical and inflammatory markers like
CRP or ESR. The inability to reproduce these findings
may be because most of the reported studies did not in-
clude enough overweight or obese patients and did not
considered the fat mas distribution or the sLep/fat mass
ratio [46–48].
In addition to the leptin resistance state observed in
our obese RA patients, we observed an association but
no correlation between anti-CCP antibodies and in-
creased sLep, sLep/sLepR and sLep/fat mass ratios ac-
cording to BMI (Fig. 1a, c, d). Notwithstanding, analysis
of partial correlation showed that after controlling for
age, fat mass and subcutaneous fat (S4ST) there was an
association between serum titers of anti-CCP and sLep
(partial r = 0.347, P = 0.033).
Anti-CCP antibodies are highly specific for RA. Pub-
lished data suggest distinct pathogenic mechanisms
underlying anti-CCP-positive RA [49]. RA patients posi-
tive for anti-CCP antibodies have more aggressive dis-
ease with early radiographic changes [49, 50]. In the
context of a proinflammatory state or autoimmune con-
dition such as RA, leptin could be a stimulator of B cells
and plasma cells to produce higher titers of anti-CCP
antibodies [51].
After classifying patients by sLep and sLepR quartiles
we observed, a trend for higher ESR, and CRP-based
and ESR-based DAS-28 with greater sLep and lower
sLepR levels. The former observations suggest that other
molecular pathways/molecules might be involved in the
regulation of leptin in RA but also the possible involve-
ment of leptin in the loss of immune tolerance towards
citrullinated proteins in RA. We suggest that leptin
could be a surrogate marker of severity or chronicity of
humoral immunity in RA in the presence of obesity.
Despite the intensive study of leptin in RA, there are
no reports on the association between sLep and anti-
CCP antibodies. We consider this study is relevant to
open new research fields to allow further examination of
the role of these molecules in the pathogenesis of RA. In
addition, it is important to evaluate the activity of en-
zymes such as PADI4 and Dickkopf-1 (DKK-1) in order
to improve the characterization of the leptin pathway in
RA.
Conclusions
In preobese and obese RA patients there is increased
production of sLep according to anti-CCP positivity.
This phenomenon suggests there is an additive effect of
chronic inflammation resulting from RA and obesity in
which leptin favors the humoral response against citrul-
linated proteins. In summary, the data observed in our
study suggest sLep could be a surrogate marker of
chronicity and humoral immunity in RA in the presence
of obesity.
Abbreviations
ACR: American College of Rheumatology; ANOVA: one-way analysis of
variance; Anti-CCP: anti-cyclic citrullinated peptide antibodies; Bcl-2: B-cell
lymphoma 2 protein; BFR: body fat ratio; BMI: body mass index; CRP: C-
reactive protein; CVD: cardiovascular disease; DAS28: Disease activity score in
28 joints; EAE: experimental autoimmune encephalomyelitis; ELISA: enzyme-
linked immunosorbent assay; ERK: extracellular-signal-regulated kinases;
Gómez-Bañuelos et al. Arthritis Research & Therapy  (2015) 17:335 Page 7 of 9
ESR: erythrocyte sedimentation rate; HOMA-IR: homeostasis model
assessment-insulin resistance; IL: interleukin; IR: insulin resistance;
IRB: Institutional Review Board; JAK: janus kinase; kDa: kiloDaltons;
MAPK: mitogen-activated protein kinases; mTOR: mammalian target of
rapamycine; NF: tumor necrosis factor; PI3K: phosphoinositide 3-kinase;
RA: rheumatoid arthritis; RF: rheumatoid factor; S4ST: sSum of four skinfold
thicknesses; SAD: sagittal abdominal diameter; sLep: serum leptin;
sLepR: serum leptin receptor; STAT3: Signal transducer and activator of
transcription 3; TCR: T cell receptors; Th: T helper; VFA: visceral fat area;
WHO: World Health Organization; WHR: waist to hip ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EGB, RENH and MVM conceived the study, and participated in its design and
coordination, wrote the final version of the manuscript and approved the
final version of the manuscript. BTMM, FCM, OEPM, HMR, PJPC, LGL, JIGN,
MSP, JAA and PMMR carried out the assays, helped to classify the patients
included, carried out the assays and classification and clinical evaluation of
RA patients and reviewed and approved the final version of the manuscript.
MVM and EGB carried out the analysis, and performed statistical analysis and
interpretation of data. All authors reviewed, drafted, read and approved the
manuscript.
Author details
1Instituto de Investigación en Reumatología y del Sistema
Musculoesquelético, CUCS, Universidad de Guadalajara, Sierra Mojada No.
950, Colonia Independencia, Zip code 44340 Guadalajara, Jalisco, México.
2Servicio de Reumatología, División de Medicina Interna, OPD Hospital Civil
de Guadalajara, “Dr. Juan I. Menchaca”, Salvador de Quevedo y Zubieta No.
750, Zip code 44100 Guadalajara, Jalisco, >México. 3Departamento de
Medicina Interna-Reumatología, Hospital General Regional no.110, Instituto
Mexicano del Seguro Social, Circunvalación Oblatos No. 2212, Colonia
Oblatos, Zip code 44700 Guadalajara, Jalisco, México. 4Unidad Médica de Alta
Especialidad, Centro Médico Nacional de Occidente, Instituto Mexicano del
Seguro Social, Belisario Domínguez No. 1000, Independencia Oriente, Zip
code 44340 Guadalajara, Jalisco, México.
Received: 3 July 2015 Accepted: 4 November 2015
References
1. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies,
opportunities and challenges. Nat Rev Rheumatol. 2015;11:276–89.
2. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin
resistance in patients with rheumatoid arthritis: risk reduction in a chronic
inflammatory disease. Arthritis Care Res. 2011;63:512–21.
3. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune
diseases: not a passive bystander. Autoimmun Rev. 2014;13:981–1000.
4. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and
glucose homeostasis. Nature. 2006;444:847–53.
5. MacDougald OA, Hwang CS, Fan H, Lane MD. Regulated expression of the
obese gene product (leptin) in white adipose tissue and 3 T3-L1 adipocytes.
Proc Natl Acad Sci USA. 1995;92:9034–7.
6. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, et al. Leptin
levels in human and rodent: measurement of plasma leptin and ob RNA in
obese and weight-reduced subjects. Nat Med. 1995;1:1155–61.
7. Tian G, Liang JN, Wang ZY, Zhou D. Emerging role of leptin in rheumatoid
arthritis. Clin Exp Immunol. 2014;177:557–70.
8. Ge H, Huang L, Pourbahrami T, Li C. Generation of soluble leptin receptor
by ectodomain shedding of membrane-spanning receptors in vitro and in
vivo. J Biol Chem. 2002;277:45898–903.
9. Huang L, Wang Z, Li C. Modulation of circulating leptin levels by its soluble
receptor. J Biol Chem. 2001;276:6343–9.
10. Liu C, Liu XJ, Barry G, Ling N, Maki RA, De Souza EB. Expression and
characterization of a putative high affinity human soluble leptin receptor.
Endocrinology. 1997;138:3548–54.
11. Zhang J, Scarpace PJ. The soluble leptin receptor neutralizes leptin-
mediated STAT3 signalling and anorexic responses in vivo. Br J Pharmacol.
2009;158:475–82.
12. Lou PH, Yang G, Huang L, Cui Y, Pourbahrami T, Radda GK, et al. Reduced
body weight and increased energy expenditure in transgenic mice over-
expressing soluble leptin receptor. PLoS One. 2010;5:e11669.
13. Sandhofer A, Laimer M, Ebenbichler CF, Kaser S, Paulweber B, Patsch JR.
Soluble leptin receptor and soluble receptor-bound fraction of leptin in the
metabolic syndrome. Obes Res. 2003;11:760–8.
14. Laimer M, Ebenbichler CF, Kaser S, Sandhofer A, Weiss H, Nehoda H, et al.
Weight loss increases soluble leptin receptor levels and the soluble receptor
bound fraction of leptin. Obes Res. 2002;10:597–601.
15. Zastrow O, Seidel B, Kiess W, Thiery J, Keller E, Bottner A, et al. The soluble
leptin receptor is crucial for leptin action: evidence from clinical and
experimental data. Int J Obes Relat Metab Disord. 2003;27:1472–8.
16. Knobelspies H, Zeidler J, Hekerman P, Bamberg-Lemper S, Becker W.
Mechanism of attenuation of leptin signaling under chronic ligand
stimulation. BMC Biochem. 2010;11:2.
17. Pal R, Sahu A. Leptin signaling in the hypothalamus during chronic central
leptin infusion. Endocrinology. 2003;144:3789–98.
18. Salazar-Paramo M, Gonzalez-Ortiz M, Gonzalez-Lopez L, Sanchez-Ortiz A,
Valera-Gonzalez IC, Martinez-Abundis E, et al. Serum leptin levels in patients
with rheumatoid arthritis. J Clin Rheumatol. 2001;7:57–9.
19. Targonska-Stepniak B, Majdan M, Dryglewska M. Leptin serum levels in
rheumatoid arthritis patients: relation to disease duration and activity.
Rheumatol Int. 2008;28:585–91.
20. Seven A, Guzel S, Aslan M, Hamuryudan V. Serum and synovial fluid leptin
levels and markers of inflammation in rheumatoid arthritis. Rheumatol Int.
2009;29:743–7.
21. Bokarewa M, Bokarew D, Hultgren O, Tarkowski A. Leptin consumption in
the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis.
2003;62:952–6.
22. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, Huang KC, et al. Leptin
induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and
promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cell
Signal. 2008;20:1478–88.
23. Muraoka S, Kusunoki N, Takahashi H, Tsuchiya K, Kawai S. Leptin stimulates
interleukin-6 production via janus kinase 2/signal transducer and activator
of transcription 3 in rheumatoid synovial fibroblasts. Clin Exp Rheumatol.
2013;31:589–95.
24. Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O, et al. Serum level
of adiponectin is a surrogate independent biomarker of radiographic
disease progression in early rheumatoid arthritis: results from the ESPOIR
cohort. Arthritis Res Ther. 2013;15:R210.
25. Kang Y, Park HJ, Kang MI, Lee HS, Lee SW, Lee SK, et al. Adipokines,
inflammation, insulin resistance, and carotid atherosclerosis in patients with
rheumatoid arthritis. Arthritis Res Ther. 2013;15:R194.
26. Olama SM, Senna MK, Elarman M. Synovial/serum leptin ratio in rheumatoid
arthritis: the association with activity and erosion. Rheumatol Int.
2012;32:683–90.
27. Xibille-Friedmann D, Bustos-Bahena C, Hernandez-Gongora S, Burgos-Vargas R,
Montiel-Hernandez JL. Two-year follow-up of plasma leptin and other
cytokines in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:930–1.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
29. WHO. Obesity: preventing and managing the global epidemic. Report of a
WHO Consultation. WHO Technical Report Series 894. Geneva: World Health
Organization, 2000.
30. Durnin JV, Rahaman MM.The assessment of the amount of fat in the
human body from measurements of skinfold thickness. 1967. Br J Nutr.
2003 Jan 89;1:147–55.
31. Nagai M, Komiya H, Mori Y, Ohta T, Kasahara Y, Ikeda Y. Development of a
new method for estimating visceral fat area with multi-frequency
bioelectrical impedance. Tohoku J Exp Med. 2008;214:105–12.
32. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB,
van Riel PL. Modified disease activity scores that include twenty-eight-joint
counts. Development and validation in a prospective longitudinal study of
patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
33. Wintrobe MM, Landsberg JW. A standardized technique for the blood
sedimentation test. 1935. Am J Med Sci. 2013 Aug 346;2:148–53.
34. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment
(HOMA) evaluation uses the computer program. Diabetes Care.
1998;21:2191–2.
Gómez-Bañuelos et al. Arthritis Research & Therapy  (2015) 17:335 Page 8 of 9
35. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP.
Identification of individuals with insulin resistance using routine clinical
measurements. Diabetes. 2005;54:333–9.
36. Fried SK, Ricci MR, Russell CD, Laferrere B. Regulation of leptin production in
humans. J Nutr. 2000;130:3127S–31.
37. Lee JW, Swick AG, Romsos DR. Leptin constrains phospholipase C-protein
kinase C-induced insulin secretion via a phosphatidylinositol 3-kinase-
dependent pathway. Exp Biol Med. 2003;228:175–82.
38. Agrawal S, Gollapudi S, Su H, Gupta S. Leptin activates human B cells to
secrete TNF-alpha, IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2
signaling pathway. J Clin Immunol. 2011;31:472–8.
39. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate
leptin synthesis and secretion. Am J Physiol Endocrinol Metab.
2009;296:E1230–8.
40. Matarese G, La Cava A, Sanna V, Lord GM, Lechler RI, Fontana S, et al.
Balancing susceptibility to infection and autoimmunity: a role for leptin?
Trends Immunol. 2002;23:182–7.
41. Procaccini C, Lourenco EV, Matarese G, La Cava A. Leptin signaling: A key
pathway in immune responses. Curr Signal Transduct Ther. 2009;4:22–30.
42. Tian G, Liang JN, Pan HF, Zhou D. Increased leptin levels in patients with
rheumatoid arthritis: a meta-analysis. Ir J Med Sci. 2014;183:659–66.
43. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007;4:1–13.
44. De Rosa V, Procaccini C, La Cava A, Chieffi P, Nicoletti GF, Fontana S, et al.
Leptin neutralization interferes with pathogenic T cell autoreactivity in
autoimmune encephalomyelitis. J Clin Invest. 2006;116:447–55.
45. Amarilyo G, Iikuni N, Shi FD, Liu A, Matarese G, La Cava A. Leptin promotes
lupus T-cell autoimmunity. Clin Immunol. 2013;149:530–3.
46. Toussirot E, Nguyen NU, Dumoulin G, Aubin F, Cedoz JP, Wendling D.
Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin
levels with bone mass and body composition in patients with rheumatoid
arthritis. Rheumatology. 2005;44:120–5.
47. Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW.
Markers of inflammation are negatively correlated with serum leptin in
rheumatoid arthritis. Ann Rheum Dis. 2005;64:1195–8.
48. Harle P, Sarzi-Puttini P, Cutolo M, Straub RH. No change of serum levels of
leptin and adiponectin during anti-tumour necrosis factor antibody
treatment with adalimumab in patients with rheumatoid arthritis. Ann
Rheum Dis. 2006;65:970–1.
49. Mouterde G, Lukas C, Goupille P, Flipo RM, Rincheval N, Daures JP, et al.
Association of anticyclic citrullinated peptide antibodies and/or rheumatoid
factor status and clinical presentation in early arthritis: results from the
ESPOIR cohort. J Rheumatol. 2014;41:1614–22.
50. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW.
Antibodies to citrullinated proteins and differences in clinical progression of
rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–58.
51. Gupta S, Agrawal S, Gollapudi S. Increased activation and cytokine secretion
in B cells stimulated with leptin in aged humans. Immun Ageing. 2013;10:3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gómez-Bañuelos et al. Arthritis Research & Therapy  (2015) 17:335 Page 9 of 9
